Drug Deal Disclosure Act
Summary
The Drug Deal Disclosure Act (S4355) is an early-stage bill requiring HHS to publicly release documents on drug pricing agreements referencing international prices. With no Republican cosponsors and only a committee referral, passage is unlikely. No near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S4355 is a transparency bill targeting drug pricing deals, but it is early-stage and lacks bipartisan support.
- 2.No immediate market impact; the bill is unlikely to advance in the 119th Congress.
- 3.Investors should monitor for committee hearings or bipartisan amendments, but currently no actionable signal.
Market Implications
No market implications at this stage. The bill is procedural and has not moved beyond committee referral. Pharmaceutical companies face no immediate disclosure risk. Investors should ignore this bill until it gains bipartisan traction or advances to a floor vote.
Full Analysis
- What happened: On April 21, 2026, Sen. Wyden introduced S4355, the Drug Deal Disclosure Act. It was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill mandates that HHS publicly disclose all records related to most-favored-nation pricing agreements and other confidential drug pricing deals entered into after January 20, 2025, between the federal government and drug manufacturers. 2) The money trail: This is an authorization bill with no funding specified. It imposes a disclosure requirement, not a spending program. Actual enforcement would rely on existing HHS resources. 3) Convergence: No related signals or procurement data were provided beyond a companion bill (HR9699) in the House, which is also in early committee stages. No direct or industry convergence with other government actions is identifiable. 4) Structural winners and losers: The bill targets transparency in drug pricing. If enacted, it could pressure pharmaceutical companies that have entered into international reference pricing agreements, potentially exposing pricing strategies and leading to public pressure for lower prices. However, the bill has no Republican support (all 18 cosponsors are Democrats plus Sen. Sanders), and the 119th Congress is divided. The legislative path is long and uncertain. 5) Timeline: The bill is at the earliest stage—referred to committee. No hearings, markups, or votes scheduled. Passage in this Congress is highly unlikely without bipartisan support.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers, and for other purposes.
Most Favored Patient Act of 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →